Emcure Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported sales was INR 23,634.78 million compared to INR 19,626.3 million a year ago. Revenue was INR 23,653.31 million compared to INR 19,665.26 million a year ago. Net income was INR 2,305.41 million compared to INR 1,537.22 million a year ago. Basic earnings per share from continuing operations was INR 12.16 compared to INR 8.12 a year ago. Diluted earnings per share from continuing operations was INR 12.16 compared to INR 8.12 a year ago.
For the nine months, sales was INR 67,338.37 million compared to INR 57,797.52 million a year ago. Revenue was INR 67,425.09 million compared to INR 58,425.6 million a year ago. Net income was INR 6,809.58 million compared to INR 4,923.75 million a year ago. Basic earnings per share from continuing operations was INR 35.93 compared to INR 26.44 a year ago. Diluted earnings per share from continuing operations was INR 35.93 compared to INR 26.44 a year ago.
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
